Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study
- 8 September 2020
- journal article
- research article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 53 (5), 612-619
- https://doi.org/10.1016/j.dld.2020.08.007
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
- Bristol-Myers Squibb
- Gilead Sciences
This publication has 37 references indexed in Scilit:
- Diagnosis and Management of Hepatitis C Infection in Primary Care SettingsJournal of General Internal Medicine, 2018
- Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy2018
- Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic reviewBMC Infectious Diseases, 2017
- Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialThe Lancet Infectious Diseases, 2017
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosisJournal of Hepatology, 2017
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2016
- Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyHealth and Quality of Life Outcomes, 2013
- Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infectionDigestive and Liver Disease, 2012
- The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activitiesJournal of Medical Economics, 2011
- Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important differenceCurrent Medical Research and Opinion, 2007